Bevacizumab and capecitabine in relapsed platinum-resistant epithelial carcinoma of ovary: A retrospective study

Background: Relapsed platinum-resistant epithelial carcinoma of the ovaryis a disease with a dismal prognosis. Bevacizumaband capecitabinehave been used in carcinoma of ovaryboth as a single agent and with other chemotherapeutic medicine. A retrospective study has been performed to assess the efficacy of bevacizumab+ capecitabinein relapsed platinum-resistant epithelial carcinoma of the ovary. Materials and Methods: Patients who suffered from relapsed platinum-resistant epithelial carcinoma of the ovaryand received bevacizumaband capecitabinewere included in the present study. The primary objective of this study was to assess response rate and progression-free survival (PFS). Treatment: Patients received capecitabineat a dose of 1250 mg/m2 twice daily from day 1 to day 14 in each cycle. Bevacizumabwas given at a dose of 7.5 mg/kg on day 1 in each cycle. The cycle was repeated in every 3 weeks. Response evaluation was done using the Response Evaluation Criteriain Solid Tumorcriteria and by Rustin criteria. Statistical Analysis: Statistical analysis was done using statistical software (SPSS 16, SPSS for Windows, SPSS Inc., Chicago, IL, USA). Results: We analyzed the data of 32 patients. The PFS was 10.51 (95% confidence interval [CI], 8.65–12.37) months. The overall survival (OS) was 20.53 (95% CI, 17.21–23.85) months. Four (12.5%) patients achieved complete response. Eighteen (56.25%) patients achieved partial response. The response rate was 68.75%. Four (12.5%) patients had progressive disease. Conclusion: Response rate, PFS, and OS of patients in this study are comparable to those of other published studies. Hence, bevacizumab+ capecitabinecan be used in relapsed platinum-resistant carcinoma of the ovary. The incidence and severity of bevacizumab-induced side effects are relatively lower in this study. Hence, bevacizumabcan be given at a lower dose with comparable efficacy and tolerable side effects.